Alnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a research report released on Tuesday. Other equities research analysts have also issued reports about the stock. Evercore ISI decreased their target price on shares of Alnylam Pharmaceuticals from $252.00 to $210.00 in a research note […]

Related Keywords

Sanfordc Bernstein ,Stifel Nicolaus ,Alnylam Pharmaceuticals Company Profile ,Alnylam Pharmaceuticals Inc ,News Ratings For Alnylam Pharmaceuticals Daily ,Analyst Recommendations For Alnylam Pharmaceuticals ,Citigroup ,Alnylam Pharmaceuticals ,Meiji Yasuda Asset Management Co Ltd ,Vanguard Personalized Indexing Management ,Morgan Stanley ,Alnylam Pharmaceuticals Stock Down ,Free Report ,Moderate Buy ,Pharmaceuticals Stock Down ,Financial Advisors ,Personalized Indexing Management ,Greenleaf Trust ,Get Free Report ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Upgrade ,Stocknews Com ,